利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

24 条记录 (耗时 0.022 秒)

    PYRAZINYL SUBSTITUTED PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY
    3.
    发明授权
    PYRAZINYL SUBSTITUTED PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY 有权
    具有CXCR3拮抗活性的吡嗪基取代的哌嗪 - 哌啶

    公开(公告)号：EP1856098B1

    公开(公告)日：2012-08-01

    申请号：EP06735090.0

    申请日：2006-02-14

    申请人： Schering Corporation ,  Pharmacopeia, LLC

    发明人： ROSENBLUM, Stuart, B. ,  KIM, Seong, Heon ,  ZENG, Qingbei ,  WONG, Michael K.C. ,  ANILKUMAR, Gopinadhan, N. ,  JIANG, Yueheng ,  YU, Wensheng ,  KOZLOWSKI, Joseph, A. ,  SHIH, Neng-Yang ,  SHANKAR, Bandarpalle, B. ,  MCGUINNESS, Brian, F. ,  DONG, Guizhen ,  ZAWACKI, Lisa, Guise ,  HOBBS, Douglas, W. ,  BALDWIN, John, J. ,  SHAO, Yuefei

    IPC分类号： C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  A61K31/445 ,  A61K31/495

    CPC分类号： C07D405/14 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14

    摘要： The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula (1): Chemical formula should be inserted here as it appears on the abstract in paper form. and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non limiting example(s) include, psoriasis), autoimmune diseases (non limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g., tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula (1).

    摘要翻译： 本申请公开了所述化合物的一种或多种对映异构体，立体异构体，旋转异构体，互变异构体，外消旋体或前药，或所述化合物或所述前药的药学上可接受的盐，溶剂合物或酯，所述化合物具有式 1）：化学式应插入此处，因为它以摘要形式出现在纸上。 及其药学上可接受的盐，溶剂化物和酯。 还公开了治疗趋化因子介导的疾病的方法，例如姑息性治疗，治愈性治疗，某些疾病和病症的预防性治疗，例如炎性疾病（非限制性实例包括牛皮癣），自身免疫性疾病（非限制性实例（ 包括类风湿性关节炎，多发性硬化症），移植排斥（非限制性实例包括同种异体移植排斥，异种移植排斥），感染性疾病（例如结核性麻风），固定药疹，皮肤迟发型超敏反应，眼科 炎症，I型糖尿病，病毒性脑膜炎和使用式（1）化合物的肿瘤。

    HETEROCYCLIC COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY
    9.
    发明公开
    HETEROCYCLIC COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY 审中-公开
    与CXCR3拮抗剂活性的杂环化合物

    公开(公告)号：EP2094688A1

    公开(公告)日：2009-09-02

    申请号：EP07863159.5

    申请日：2007-12-20

    申请人： Schering Corporation ,  Pharmacopeia, Inc.

    发明人： ZENG, Qingbei ,  ROSENBLUM, Stuart B. ,  KOZLOWSKI, Joseph A. ,  SHIH, Neng-Yang ,  MCGUINNESS, Brian F. ,  HOBBS, Douglas W.

    IPC分类号： C07D401/14 ,  A61K31/495 ,  A61P29/00

    CPC分类号： C07D401/14

    摘要： The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1 or Formula 5: [Chemical formulas should be inserted here as they appear on abstract in paper form.] or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non limiting example(s) include, psoriasis), autoimmune diseases (non limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g , tuberculoid leprosy), fixed drug eruptions, cutaneous delayed type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.